These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29395274)

  • 1. Cannabidiol for drop seizures in Lennox-Gastaut syndrome.
    Varadkar S
    Lancet; 2018 Mar; 391(10125):1006-1007. PubMed ID: 29395274
    [No Abstract]   [Full Text] [Related]  

  • 2. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
    Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
    N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of Cannabidiol to Current Antiepileptic Therapy Reduces Drop Seizures in Children and Adults With Treatment-Resistant Lennox-Gastaut Syndrome.
    Ostrovsky DA; Ehrlich A
    Explore (NY); 2018; 14(4):311-313. PubMed ID: 29887290
    [No Abstract]   [Full Text] [Related]  

  • 5. Cannabidiol in the Lennox-Gastaut Syndrome.
    Devinsky O; Patel AD; VanLandingham KE
    N Engl J Med; 2018 Aug; 379(8):795. PubMed ID: 30134132
    [No Abstract]   [Full Text] [Related]  

  • 6. Cannabidiol in the Lennox-Gastaut Syndrome.
    Feng L; Hoyland L; Poulton A
    N Engl J Med; 2018 Aug; 379(8):794. PubMed ID: 30136545
    [No Abstract]   [Full Text] [Related]  

  • 7. Cannabidiol in the Lennox-Gastaut Syndrome.
    Tampaki EC; Tampakis A; Pantos K
    N Engl J Med; 2018 Aug; 379(8):794. PubMed ID: 30136546
    [No Abstract]   [Full Text] [Related]  

  • 8. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
    Bergmann KR; Broekhuizen K; Groeneveld GJ
    Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drop seizures cut by cannabidiol.
    Ridler C
    Nat Rev Neurol; 2018 Jul; 14(7):380-381. PubMed ID: 29858607
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
    Hollenack K; Marshall J
    Pharmacoeconomics; 2021 Apr; 39(4):473-475. PubMed ID: 33674999
    [No Abstract]   [Full Text] [Related]  

  • 12. Authors' Reply to Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
    Neuberger EE; Carlson JJ; Veenstra DL
    Pharmacoeconomics; 2021 Apr; 39(4):477-478. PubMed ID: 33674997
    [No Abstract]   [Full Text] [Related]  

  • 13. Cannabinoids for drug-resistant seizures in a critically ill patient-Case report and literature review.
    Capra S; Narayan SW; Parratt K; Patanwala AE
    J Clin Pharm Ther; 2020 Jun; 45(3):570-572. PubMed ID: 31770462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabidiol for epilepsy: trying to see through the haze.
    Detyniecki K; Hirsch LJ
    Lancet Neurol; 2016 Mar; 15(3):235-7. PubMed ID: 26776916
    [No Abstract]   [Full Text] [Related]  

  • 15. Lennox-Gastaut syndrome: New treatments and treatments under investigation.
    Auvin S
    Rev Neurol (Paris); 2020 Jun; 176(6):444-447. PubMed ID: 32409177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
    Striano P; McMurray R; Santamarina E; Falip M
    Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects of cannabinoids.
    Anciones C; Gil-Nagel A
    Epileptic Disord; 2020 Jan; 22(S1):29-32. PubMed ID: 31941644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clobazam and Aggression-Related Adverse Events in Pediatric Patients With Lennox-Gastaut Syndrome.
    Paolicchi JM; Ross G; Lee D; Drummond R; Isojarvi J
    Pediatr Neurol; 2015 Oct; 53(4):338-42. PubMed ID: 26245776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome.
    Kim HJ; Kim SH; Kang HC; Lee JS; Chung HJ; Kim HD
    Pediatr Neurol; 2014 Oct; 51(4):527-31. PubMed ID: 25266616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the modified Atkins diet in Lennox Gastaut syndrome.
    Sharma S; Jain P; Gulati S; Sankhyan N; Agarwala A
    J Child Neurol; 2015 Apr; 30(5):576-9. PubMed ID: 24659735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.